Effects of arzoxifene on fracture incidence in postmenopausal women with osteoporosis or with low bone mass
Jean‐Yves Reginster(King Saud University), S. R. Cummings(University of California, San Francisco), P. Miller, Michael R. McClung(Bone Health and Osteoporosis Foundation), David A. Cox(Bon Secours Heart & Vascular Institute), B. Mitlak(Eli Lilly (United States)), Messan G. Amewou-Atisso, John L. Stock(Eli Lilly (United States)), C. Christiansen
ORBi (University of Liège)
May 1, 2010
Cited by 2
Related Papers
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.4k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2012|2.9k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2018|1.8k
Relationship Between Osteoporosis and Cardiovascular Disease in Postmenopausal Women
|Journal of Bone and Mineral Research|2005|538
Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of Age
|New England Journal of Medicine|1998|487